Literature DB >> 20819529

Coagulase-negative staphylococcus and enterococcus as predominant pathogens in liver transplant recipients with Gram-positive coccal bacteremia.

Shao-hua Shi1, Hai-shen Kong, Chang-ku Jia, Jian Xu, Wen-jin Zhang, Wei-lin Wang, Yan Shen, Min Zhang, Shu-sen Zheng.   

Abstract

BACKGROUND: Gram-positive bacteria such as Staphylococcus aureus have been a common cause of infection among liver transplant (LT) recipients in recent decades. The understanding of local epidemiology and its evolving trends with regard to pathogenic spectra and antibiotic susceptibility is beneficial to prophylactic and empiric treatment for LT recipients. This study aimed to investigate etiology, timing, antibiotic susceptibility and risk factors for multidrug resistant (MDR) Gram-positive coccal bacteremia after LT.
METHODS: A cohort analysis of prospectively recorded data was performed to investigate etiologies, timing, antibiotic susceptibility and risk factors for MDR Gram-positive coccal bacteremia in 475 LT recipients.
RESULTS: In 475 LT recipients in the first six months after LT, there were a total of 98 episodes of bacteremia caused by Gram-positive cocci in 82 (17%) patients. Seventy-five (77%) bacteremic episodes occurred in the first post-LT month. The most frequent Gram-positive cocci were methicillin-resistant coagulase-negative staphylococcus (CoNS, 46 isolates), methicillin-resistant Staphylococcus aureus (MRSA, 13) and enterococcus (34, E. faecium 30, E. faecalis 4). In all Gram-positive bacteremic isolates, 59 of 98 (60%) were MDR. Gram-positive coccal bacteremia and MDR Gram-positive coccal bacteremia predominantly occurred in patients with acute severe exacerbation of chronic hepatitis B and with fulminant/subfulminant hepatitis. Four independent risk factors for development of bacteremia caused by MDR Gram-positive coccus were: LT candidates with encephalopathy grades II - IV (P = 0.013, OR: 16.253, 95%CI: 1.822 - 144.995), pre-LT use of empirical antibiotics (P = 0.018, OR: 1.029, 95%CI: 1.002 - 1.057), post-LT urinary tract infections (P < 0.001, OR: 20.340, 95%CI: 4.135 - 100.048) and abdominal infection (P = 0.004, OR: 2.820, 95%CI: 1.122 - 10.114). The main infectious manifestations were coinfections due to gram-positive cocci and gram-negative bacilli.
CONCLUSIONS: Methicillin-resistant CoNS and enterococci are predominant pathogens among LT recipients with Gram-positive coccal bacteremia. Occurrences of Gram-positive coccal bacteremia may be associated with the severity of illness in the perioperative stage.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20819529

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  5 in total

1.  Bloodstream infections caused by Enterococcus spp: A 10-year retrospective analysis at a tertiary hospital in China.

Authors:  Jin-Xin Zheng; Hui Li; Zhang-Ya Pu; Hong-Yan Wang; Xiang-Bin Deng; Xiao-Jun Liu; Qi-Wen Deng; Zhi-Jian Yu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-04-11

Review 2.  Multidrug-resistant bacterial infections after liver transplantation: an ever-growing challenge.

Authors:  Guilherme Santoro-Lopes; Erika Ferraz de Gouvêa
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

3.  Staphylococcus aureus bacteremias following liver transplantation: a clinical analysis of 20 cases.

Authors:  Jiandang Zhou; Hui Huang; Shan Liu; Ping Yu; Qiquan Wan
Journal:  Ther Clin Risk Manag       Date:  2015-06-12       Impact factor: 2.423

Review 4.  Methicillin-resistant Staphylococcus aureus bacteremia among liver transplant recipients: epidemiology and associated risk factors for morbidity and mortality.

Authors:  Taohua Liu; Yuezhong Zhang; Qiquan Wan
Journal:  Infect Drug Resist       Date:  2018-05-03       Impact factor: 4.003

Review 5.  Management of bacterial and fungal infections in end stage liver disease and liver transplantation: Current options and future directions.

Authors:  Elda Righi
Journal:  World J Gastroenterol       Date:  2018-10-14       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.